LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade.
Jacobi
G H
GH
Urologische Fachpraxis, Duisburg, FRG.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002064:Buserelin / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D017329:Triptorelin Pamoate
D000970:Antineoplastic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D002064:Buserelin